Int J Arrhythm.  2024 Sep;25(3):12. 10.1186/s42444-024-00121-w.

Clinical role of genetic testing for the Brugada syndrome overlapping with arrhythmogenic cardiomyopathy

•  Jeong J
• Lee H
•  Choi Y
• Kim Y
• Shim J
• Hwang J
•  Yun S
•  Cho Y
• Kim Y
• Choi J

• KMID: 2559701
• DOI: http://doi.org/10.1186/s42444-024-00121-w

Abstract

Background
Brugada syndrome (BrS) and arrhythmogenic cardiomyopathy (ACM) are inherited cardiac diseases that may predispose to ventricular arrhythmia. Although overlapping features between BrS and ACM have been demonstrated previously, it remains to be determined whether genetic testing for ACM-related genes is needed in BrS probands. Method Based on a single-center, retrospective registry of BrS, we aimed to verify genetic profiles of BrS using a next-generation sequencing panel, and further analyzed genetic testing of ACM-related variants in Brugada phenotypes.
Results
Among a total of 119 Brugada phenotypes, 114 patients (95.8%) were male and the mean age of onset was 43.6 years. Genetic variants were identified in 25 of the 42 patients who underwent genetic testing. Fifteen patients had BrS-related genotypes, including SCN5A in 6 patients, and non-SCN5A genes in 9 patients (SCN10A, HCN4, SCN3B, and KCNE3). Nineteen patients underwent additional genetic testing with cardiomyopathy panel, which revealed ACM-related genotypes (2 PKP2, 1 DSG2, 1 TMEM43, 1 JUP, and 1 DSP) present in 6 patients (31.5%). None of the patients had structural or electrocardiographic features that fulfilled the diagnostic criteria for ACM.
Conclusions
In clinical setting, ACM-related genes were identified in a significant proportion of Brugada phenotypes, supporting the argument that genetic testing of ACM overlapping is needed. Follow-up imaging studies should be considered to monitor if the disease progresses to ACM.

Keyword

Brugada syndrome; Arrhythmogenic cardiomyopathy; High-throughput nucleotide sequencing